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Abstract
Background: Chemotherapy is often used before a resection for colorectal liver metastases. After
chemotherapy, metastases may disappear on cross-sectional imaging but residual metastatic disease
may still exist. The aim of this retrospective study was to investigate the impact of new advancements
in imaging technology such as magnetic resonance imaging (MRI) with liver-specific contrast (Gd-EOB-
DTPA) and contrast-enhanced intra-operative ultrasound (CE-IOUS) on disappearing liver metastases
(DLM).
Methods: Twenty-nine patients with one or more DLM undergoing surgical exploration were included.
Pre-operative imaging consisted of contrast-enhanced multi-detector computed tomography (MDCT)
and/or MRI with liver-specific contrast. At surgery, CE-IOUS was used when tumours known from pre-
chemotherapy imaging were not found by inspection or intra-operative ultrasound.
Results: Patients presented 66 DLM. At surgical exploration, 42 DLM were identified and treated
(64%). CE-IOUS detected one additional DLM not found by intra-operative ultrasound. For metastases
≤10 mm on histological analysis, imaging sensitivities for MRI and MDCT before surgery but after
chemotherapy were 26/49 (53%) and 24/66 (36%), respectively.
Conclusion: A majority of DLM are identified during surgery using intra-operative ultrasound, with
only little additional value of CE-IOUS. The sensitivities of post-chemotherapy imaging modalities for
small metastases are low in the setting of DLM. For surgical planning, an optimized pre-chemotherapy
imaging is essential.
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Introduction
Chemotherapy is used before a resection of colorectal liver metastases
either as neoadjuvant therapy or conversion therapy for the initially
irresectable disease.1,2 After effective chemotherapy, some metastases
may no longer be identifiable on cross-sectional imaging owing to
tumour shrinkage; constituting radiologically disappearing liver metas-
tases (DLM). The occurrence of DLM is not a rare event, but can
occur in up to 25% of patients undergoing systemic chemotherapy.3
However, DLM does not equate a complete pathological response as a
proportion of DLM persist as viable cancer cells and can be found dur-
ing surgical exploration using intra-operative ultrasound.4–9 The
reported intra-operative detection rate of DLM is highly variable;
between 25% and 66%, and is influenced by the sensitivity of the
imaging methods used both pre- and intra-operatively.3,9
Multidetector computed tomography (MDCT) has been
used as the standard imaging modality both before and after
chemotherapy. However, magnetic resonance imaging (MRI)
with liver-specific contrast agents have the highest sensitivity
for detecting small liver metastases.10,11 Thus, pre-operative
imaging may influence the definition of DLM. In addition, the
intra-operative detection rate of DLM could be influenced
by the use of intra-operative contrast-enhanced ultrasound
(CE-IOUS).12 The aim of the present retrospective study was
to investigate the incidence of DLM in routine clinical practice
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using modern imaging techniques including MDCT and MRI
with liver-specific contrast agent and the intra-operative
detection rate of DLM using intra-operative ultrasound and
CE-IOUS.
Patients and methods
Patients were staged before and after chemotherapy with a
three-phase hepatic protocol MDCT and/or MRI with liver-
specific contrast (Gd-EOB-DTPA). Routine protocols for
MDCT were used.13 Patients obtained oral contrast, scanned in
native phase and, after injection of intravenous ionic contrast,
scanned in the late arterial phase (15 s after threshold) and in
the portovenous phase (50 s after threshold). The MRI proto-
cols included injection of Gd-EOB-DTPA with scanning
sequences after 2, 7, 10 and 20 min.14
Images were assessed by two radiologists. A comprehensive
assessment of all imaging examinations was made in relation
to a multidisciplinary team conference at two different occa-
sions: before and after chemotherapy. A DLM was defined as a
lesion classified as malignant on pre-chemotherapy imaging,
which could not be identified on imaging after chemotherapy.
At the second multidisciplinary team conference, the number
and locations of DLM were documented.
Surgery started with a thorough exploration of the liver
through a right-sided subcostal J-incision, and an intra-opera-
tive ultrasound was performed. An intra-operative ultrasound
was performed by a radiologist using a Pro-Focus 2002 ultra-
sound scanner (BK Medical AB, Kungens kurva, Sweden). If
a tumour known from pre-chemotherapy imaging was not
identified by intra-operative ultrasound CE-IOUS was per-
formed. The CE-IOUS was concentrated on the location of
the DLM, using intravenous administration of 2.4 ml of sul-
phur hexafluoride microbubbles (Sono-Vue, Bracco Imaging
Scandinavia AB, Sweden), with continuous scanning up to
3 min.
The surgical strategy was to treat all identified tumours
either by resection or intra-operative ultrasound-guided
radiofrequency ablation. If the DLM was not found during
exploration, the initial site of DLM was resected if the site was
clearly identified and could be resected with small parenchymal
loss. Patients with DLM left in situ were followed with MDCT.
A tumour subsequently identified at the site of DLM occurring
within 6 months after surgery was considered recurrence of
DLM.
The liver specimen was cut into 5-mm slices, and the num-
ber and size of tumours were recorded. In case of resected sites
containing undetected DLM at surgery, the pathologist cut
these sections into 3-mm slices.
Univariate statistical comparisons for continuous variables
were performed using Mann–Whitney U-test. Comparison of
sensitivities of imaging techniques was made using Fisher’s
Exact Test. A P-value of < 0.05 was considered significant.
Results
Between 2011 and 2014, 288 patients underwent a liver resec-
tion for colorectal liver metastases. One hundred and seventy-
nine of these patients had received chemotherapy within
3 months of surgery. Twenty-nine patients with one or
more DLM on cross-sectional imaging after a pre-operative
chemotherapy were included in the study.
All 29 patients underwent MDCT of the abdomen and chest
for staging before initiation of chemotherapy. In seven patients,
positron emission tomography was used to rule out extrahep-
atic metastases before chemotherapy. Eighteen patients had
additional staging pre-chemotherapy with MRI with liver-
specific contrast. After chemotherapy, 14 patients had the liver
evaluated with CT only, six patients were evaluated with MRI
only, and nine patients were evaluated with both CT and MRI.
Patients had a total of 141 metastases before initiation of
chemotherapy and presented 66 DLM on cross-sectional imag-
ing after chemotherapy. Patient characteristics are shown in
Table 1.
At surgery, 42 out of 66 DLM (64%) were identified, all but
two were smaller than 10 mm. Thirty-six tumours were
resected, and six tumours were treated with radiofrequency
ablation. Histopathology classified all resected 36 lesions as
metastases, of which four were described as containing no
viable cancer cells.
Table 1 Patient characteristics
Characteristic Number or median
(range)
Age (years) 68 (48–83)
Gender (male/female) 20/9
BMI (kg/m2) 26 (19–32)
Tumours per patient pre-chemotherapy 5 (1–10)
Time from first imaging
to start of chemotherapy (days)
38 (2–71)
Chemotherapy regimen
Oxaliplatin-based 23
Irinotecan-based 6
Targeted therapy 10
Chemotherapy cycles before surgery 5 (3–16)
Time from last imaging to surgery (days) 43 (7–83)
Time from end of
chemotherapy to surgery (days)
47 (25–91)
Types of resection
Segmentectomy and/or wedge 10
Bisegmentectomy  wedge 3
Hemihepatectomy 13
Extended hemihepatectomy 3
Additional radiofrequency ablation 6
Patients with portal vein embolization 2
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Intra-operative ultrasound without contrast identified all
tumours known from pre-operative post-chemotherapy imag-
ing including DLM in 16 patients. Sixteen DLM were reported
calcified on ultrasound facilitating their identification even
when small. In the 13 patients with undetected DLM after the
intra-operative ultrasound, additional examination with
CE-IOUS revealed only one additional DLM.
A total of 24 DLM (36%) in 12 patients were un-identified
after visual inspection, palpation, intra-operative ultrasound
and CE-IOUS. The locations of 20 of these DLM were
included in the resections, without evidence of tumour on
histopathology. Four DLM were left for follow-up, of which
one recurred.
The median (range) size of DLM before chemotherapy was
10 (4–10) mm for tumours that were identified during surgery
and 8 (5–20) mm for those that were undetected during sur-
gery, without difference between groups (P = 0.424).
At surgery, an additional, from preoperative imaging
unknown, 11 tumours were found in five patients after inspec-
tion and intra-operative ultrasound. All tumours were identi-
fied as metastases on histopathology and were <10 mm in size.
Pre-chemotherapy imaging for these patients was MDCT for
two patients and MDCT and MRI for three patients.
The sensitivities of the pre-operative imaging modalities of
MDCT and MRI for detecting tumours found during surgery
are shown in Table 2. There was no difference in diagnostic
sensitivity between MDCT and MRI neither for tumours smal-
ler than 10 mm (P = 0.312) or larger tumours (P = 1.000).
Analysing the 18 patients examined with both MDCT and
MRI before chemotherapy, the number of tumours that were
classified as DLM after chemotherapy imaging were 41 if the
initial imaging was MRI and 13 if MDCT would have consti-
tuted the only pre-chemotherapy imaging modality.
Discussion
In this study, the majority (64%) of DLM was found at sur-
gery for colorectal liver metastases. This is almost in exact
agreement with the results of the study by Ferrero et al.9
including 33 patients with 67 DLM. Other studies have
shown much lower detection rates.4,6 The difference might be
because of the use of different imaging techniques previously
often including MDCT before chemotherapy and MDCT and/
or MRI before resection. The proportion of patients evaluated
with pre-chemotherapy MRI with liver-specific contrast was
high in the present study (18/29 patients). The incidence of
DLM is highly dependent of imaging modality both pre-
chemotherapy and before resection, although this has been
studied only to a limited extent. The study of Auer4 showed
that if MRI was performed before a resection there was a
greater probability to find the lesion during surgery, which
led them to recommend MRI before resection. However, in
the present study, the sensitivities of both MRI and MDCT
before resection were low (53% and 36%, respectively) for
lesions smaller than 10 mm. The same level of sensitivity
(52%) of MRI with liver-specific contrast agent after
chemotherapy has been reported previously, which was
increased to 81% by adding diffusion-weighted imaging.15
Another recent study showed that diffusion-weighted imaging
only slightly increased the sensitivity of MRI with liver-speci-
fic contrast for detecting small metastases.16 The value of
using diffusion-weighted imaging was not evaluated in the
present study.
Subgroup analysis, including the 18 patients that had both
MRI and MDCT imaging before chemotherapy, indicated that
using MRI would increase the number of DLM in a given pop-
ulation by identifying a greater number of small metastases
before chemotherapy. Consequently, relying on MDCT for pre-
chemotherapy staging should then result in a greater number
of pre-operatively unknown tumours found during surgery.
However, this is difficult to conclude from previous studies as
we have failed to identify any mentioning of ‘new’ tumours in
previous reports on DLM. In the present study, an additional
11 tumours were found in five patients. It can be debated
whether these tumours were missed lesions or new tumours
owing to progressive disease. As all patients in the present
study, by definition, had radiological responding tumours
according to RECIST17 and all ‘new’ tumours were small, it is
conceivable that the 11 tumours were missed lesions, although
a mixed response has been described.18
MRI with liver-specific contrast agents has been suggested as
a first-line imaging modality for initial imaging owing to a
higher sensitivity and specificity than other imaging modali-
ties.10 The results of the present study also indicate that
patients that are to undergo neoadjuvant or conversion
chemotherapy are best served by a pre-chemotherapy MRI
with liver-specific contrast to allow for identification of the
highest number of tumours to guide the resection strategy, as
a majority of these lesions will still be identifiable at surgery
after chemotherapy. The imaging modality after chemotherapy
could then be directed primarily to exclude progressive disease,
Table 2 Number of tumours identified pre- and intra-operatively
and sensitivities of pre-operative imaging modalities
Tumour size on
ultra-sound or
histology
Tumours identified
on MDCT before
surgery
Tumours
identified
at surgery
Sensitivity
(%)
≤10 mm 24 66 36
>10 mm 27 30 90
Tumours identified
on MRI before
surgery
Tumours
identified
at surgery
Sensitivity (%)
≤10 mm 26 49 53
>10 mm 18 19 95
MDCT, multidetector computed tomography; MRI, magnetic resonance
imaging.
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which shows a worse prognosis after a resection19 than to
identify shrinking tumours or DLM.
There is an important difference in the definition of DLM
and a complete tumour response. In the present study, DLM
constituted to a great extent missed lesions that were identified
intra-operatively. However, 24 tumours could not be found
during surgery, the site of 20 tumours were included in the
resections without histopathological evidence of a tumour. This
was interpreted as a complete response as the locations of pre-
vious tumour areas were reported to the pathologist who then
cut these areas in 3-mm-thick slices. However, a complete
response is difficult to conclude if histopathology is used as a
standard as microscopic lesions can hide inside the slices. A
better way of defining a complete response could be to observe
recurrence at the site of unresected DLM. Of the additional
four DLM that were left in place, one tumour recurred at fol-
low-up. This can be compared with the 9/27 patients with
recurrences at the site of the DLM undetected during surgery
and left in place reported by Goere et al.7, and the recurrence
of 3/7 tumours in the study by Arita et al.5
In the present study, CE-IOUS was used in the 13 patients
where intra-operative ultrasound was unable to detect all
lesions known from pre-chemotherapy imaging. In only one
patient, this examination could identify one DLM even if the
investigation was concentrated around the known location of
the DLM. This is in agreement with the study by Ferrero et al.9
who obtained no extra information using CE-IOUS in search-
ing for DLM but in sharp contrast to the results of Arita et al.5
who identified only four of 32 DLM with intra-operative ultra-
sound, but another 12 DLM using CE-IOUS. The additional
value of using CE-IOUS for identifying DLM as compared
with intra-operative ultrasound only, has also been reported by
Ruzzenente et al.20 The higher rate of detection of DLM with
intra-operative ultrasound as compared with CE-IOUS in this
study could be as a result of the presence of microcalcifica-
tions. In the radiologists’ reports on the intra-operative ultra-
sound examinations it was described that in 16 cases that the
DLM was localized by finding microcalcifications at the site of
the DLM. Calcification of tumours after chemotherapy, found
by intra-operative ultrasound, has been reported to be present
in 20%.21
The weakness of this retrospective study is primarily that there
were no standard imaging procedures before or after chemother-
apy. Patients were referred to the multidisciplinary liver board
after MDCT only or after MDCT and MRI with liver-specific
contrast, according to the local routine of the referring hospital.
In addition, the time between imaging after chemotherapy and
surgery was rather long (Table 1). However, the study reports
from a true clinical situation, the results of which could be valu-
able in the decision-making when facing DLM. With respect to
the long time between imaging and surgery, it has previously
been shown that this time period has a limited effect on tumour
growth after effective chemotherapy.22
Conclusion
A majority of DLM was found during surgery. CE-IOUS was
of almost no value for intra-operative detection of DLM; most
DLM were found by intra-operative ultrasound. The sensitivi-
ties of post-chemotherapy pre-operative imaging modalities for
small metastases are low in the setting of DLM. The pre-opera-
tive surgical strategy should be based on pre-chemotherapy
imaging with optimal quality.
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